Benzinga | Aug 5, 2021 07:22AM EDT

Galmed Pharmaceuticals Q2 EPS $(0.33) Beats $(0.38) Estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 26.92 percent decrease over losses of $(0.26) per share from the same period last year.